Talis Biomedical (TLIS) has released an update to notify the public and investors about its officers.
Talis Biomedical Corporation, following its strategic reevaluation and a significant workforce reduction, has terminated the role of Dr. Andrew Lukowiak as President and Chief Scientific Officer, effective January 14, 2024. This action is not due to any operational, policy, or accounting disagreements, and the company has no plans to appoint a successor for the position.
For further insights into TLIS corporate activity, check out TipRanks’ Insiders Trading Activity page.
